Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead oral PDE4 inhibitor prodrug, PALI-2108, and related corporate and regulatory milestones. The company focuses on autoimmune, inflammatory, and fibrotic diseases, with particular emphasis on ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).
News about Palisade Bio frequently highlights progress in its clinical programs. Recent announcements describe completion of Phase 1a and Phase 1b studies in UC, initiation and patient dosing in a Phase 1b study in FSCD, and plans to use these data to support Phase 2 IND submissions to the U.S. Food and Drug Administration. Company updates also discuss trial design elements such as safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory tissue-level and molecular analyses in intestinal biopsies and blood samples.
Investors and observers can also expect coverage of intellectual property developments, including composition-of-matter patents granted in Canada and Japan for PALI-2108 and related gut microbiota–activated PDE4 inhibitor prodrugs. Financing and capital markets activity is another recurring theme, with press releases detailing underwritten public offerings of common stock and common stock equivalents, as well as the intended use of proceeds to fund Phase 2 development in ulcerative colitis.
Additional Palisade Bio news items include participation in healthcare investor conferences, appointments of clinical and operational leaders with experience in gastroenterology and immunology, and governance matters such as stockholder meetings and special meeting outcomes. For readers following PALI, this news stream provides insight into the company’s clinical timelines, regulatory plans, patent estate, leadership, and financing decisions related to its gut-targeted PDE4 inhibitor prodrug platform.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.